Regulus Capital Expenditure Coverage Ratio from 2010 to 2024
| RGLS Stock | USD 1.64 0.07 4.46% |
Capital Expenditure Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (43.67) | Current Value (45.85) | Quarterly Volatility 551.86846404 |
Check Regulus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regulus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 215.7 K, Interest Expense of 1.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 4.03, Dividend Yield of 0.0 or PTB Ratio of 1.75. Regulus financial statements analysis is a perfect complement when working with Regulus Therapeutics Valuation or Volatility modules.
Regulus | Capital Expenditure Coverage Ratio |
Latest Regulus Therapeutics' Capital Expenditure Coverage Ratio Growth Pattern
Below is the plot of the Capital Expenditure Coverage Ratio of Regulus Therapeutics over the last few years. It is Regulus Therapeutics' Capital Expenditure Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regulus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Expenditure Coverage Ratio | 10 Years Trend |
|
Capital Expenditure Coverage Ratio |
| Timeline |
Regulus Capital Expenditure Coverage Ratio Regression Statistics
| Arithmetic Mean | (254.33) | |
| Geometric Mean | 62.24 | |
| Coefficient Of Variation | (216.99) | |
| Mean Deviation | 346.39 | |
| Median | (45.85) | |
| Standard Deviation | 551.87 | |
| Sample Variance | 304,559 | |
| Range | 2K | |
| R-Value | (0.18) | |
| Mean Square Error | 316,870 | |
| R-Squared | 0.03 | |
| Significance | 0.51 | |
| Slope | (22.72) | |
| Total Sum of Squares | 4.3M |
Regulus Capital Expenditure Coverage Ratio History
About Regulus Therapeutics Financial Statements
Regulus Therapeutics shareholders use historical fundamental indicators, such as Capital Expenditure Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Regulus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Regulus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Regulus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Expenditure Coverage Ratio | (43.67) | (45.85) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.